-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, Daiichi Sankyo (China) issued an announcement stating that the company transferred the production and sales rights of Colabituto preparations in mainland China and the entire equity of the production company producing the preparations to YaoPharma.
The transfer will be completed in August 2022, and the transfer profit arising from the share transfer is expected to be included in March 2023
.
It is reported that after the completion of this transaction, YaoPharma will obtain 100% equity of Daiichi Sankyo Pharmaceutical (Beijing) and the product rights of Colabituto tablets and injections in mainland China
.
According to the data, Daiichi Sankyo (Beijing) is a 100% affiliated subsidiary of Daiichi Sankyo (China), and Chongqing Yaoyou is an important holding subsidiary of Fosun Pharma
.
Regarding the transfer of business and equity interests in subsidiaries of Daiichi Sankyo (China), the industry believes that this is mainly due to intensified market competition and the "mid-life crisis" of patent expiration.
In order to cope with challenges and changes, Daiichi Sankyo adjusted related business products, and turned its attention to anti-tumor drugs, and made strong forward-looking bets on ADC drugs
.
Before this transfer, Daiichi Sankyo had successively sold mature product businesses
.
Last year, Daiichi Sankyo transferred the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa
.
At that time, Daiichi Sankyo said that in the future, while optimizing its business, it would focus more of its resources on the field of oncology
.
At present, in the context of changes in the domestic pharmaceutical environment, in fact, many multinational pharmaceutical companies have the same strategy in China as the transformation of Daiichi Sankyo.
In recent years, Roche, Eli Lilly, GSK, Takeda, Pfizer and other companies have also They have already started to speed up their weight loss and adjust their business in China
.
In February this year, AstraZeneca China revealed to the public that it had decided to merge the Respiratory and Autoimmune Division, Digestion and Respiratory Nebulization Division to establish the Respiratory, Digestive and Autoimmune Division; the new division will be headed by the current Vice President of AstraZeneca China.
, led by Lin Xiao, head of the respiratory and autoimmune business department
.
The new structure adjustment has been implemented from February 15th
.
By the end of 2021, UCB will adjust the staff of Parkinson's team
.
The adjusted product line is Eupro (rotigotine
.
It is understood that the reason for the layoff is because Eupro (rotigotine) has negotiated national medical insurance twice, but both failed to obtain medical insurance
.
In this regard, the company believes that the product The overall output was too low and the business volume was too low to implement this adjustment plan
.
In June 2021, Eli Lilly sold the rights of Cialis in the Chinese mainland market to Menarini, an Italian pharmaceutical company
.
Eli Lilly sold Cialis Afterwards, resources will be concentrated to accelerate the launch of new products and new indications in key disease areas in China, and to optimize the business promotion model.
.
.
In addition to multinational pharmaceutical companies, many local companies have also chosen to “slim down”
.
Since the beginning of this year, many pharmaceutical companies have The company has made many new moves in this regard
.
On January 7, Hainan Shuangcheng Pharmaceutical issued an announcement saying that it agreed to its holding subsidiary Ningbo Shuangcheng Pharmaceutical, which plans to acquire Memantine Hydrochloride Tablets (5 mg) for RMB 6 million.
, 10mg) related specific intellectual property rights and production technologies in the designated area were granted to Baishan Pharmaceutical (Huzhou)
.
On the 25th, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to 32.
0988 million yuan.
The price will transfer 4.
9383% of the equity held in Minowei to Pingtan Wenzhou Ruiji Investment Partnership (Limited Partnership) and Pingtan Fanrun Enterprise Management Partnership (Limited Partnership).
In general, a large number of domestic and foreign pharmaceutical companies have In the sale or transfer of related businesses, some of them have to sell and transfer "returning blood" due to the impact of their performance
.
Others continue to gather resources and relocate
.
It is foreseeable that in 2022, the competition in the pharmaceutical market will be Disclaimer
: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The transfer will be completed in August 2022, and the transfer profit arising from the share transfer is expected to be included in March 2023
.
It is reported that after the completion of this transaction, YaoPharma will obtain 100% equity of Daiichi Sankyo Pharmaceutical (Beijing) and the product rights of Colabituto tablets and injections in mainland China
.
According to the data, Daiichi Sankyo (Beijing) is a 100% affiliated subsidiary of Daiichi Sankyo (China), and Chongqing Yaoyou is an important holding subsidiary of Fosun Pharma
.
Regarding the transfer of business and equity interests in subsidiaries of Daiichi Sankyo (China), the industry believes that this is mainly due to intensified market competition and the "mid-life crisis" of patent expiration.
In order to cope with challenges and changes, Daiichi Sankyo adjusted related business products, and turned its attention to anti-tumor drugs, and made strong forward-looking bets on ADC drugs
.
Before this transfer, Daiichi Sankyo had successively sold mature product businesses
.
Last year, Daiichi Sankyo transferred the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa
.
At that time, Daiichi Sankyo said that in the future, while optimizing its business, it would focus more of its resources on the field of oncology
.
At present, in the context of changes in the domestic pharmaceutical environment, in fact, many multinational pharmaceutical companies have the same strategy in China as the transformation of Daiichi Sankyo.
In recent years, Roche, Eli Lilly, GSK, Takeda, Pfizer and other companies have also They have already started to speed up their weight loss and adjust their business in China
.
In February this year, AstraZeneca China revealed to the public that it had decided to merge the Respiratory and Autoimmune Division, Digestion and Respiratory Nebulization Division to establish the Respiratory, Digestive and Autoimmune Division; the new division will be headed by the current Vice President of AstraZeneca China.
, led by Lin Xiao, head of the respiratory and autoimmune business department
.
The new structure adjustment has been implemented from February 15th
.
By the end of 2021, UCB will adjust the staff of Parkinson's team
.
The adjusted product line is Eupro (rotigotine
.
It is understood that the reason for the layoff is because Eupro (rotigotine) has negotiated national medical insurance twice, but both failed to obtain medical insurance
.
In this regard, the company believes that the product The overall output was too low and the business volume was too low to implement this adjustment plan
.
In June 2021, Eli Lilly sold the rights of Cialis in the Chinese mainland market to Menarini, an Italian pharmaceutical company
.
Eli Lilly sold Cialis Afterwards, resources will be concentrated to accelerate the launch of new products and new indications in key disease areas in China, and to optimize the business promotion model.
.
.
In addition to multinational pharmaceutical companies, many local companies have also chosen to “slim down”
.
Since the beginning of this year, many pharmaceutical companies have The company has made many new moves in this regard
.
On January 7, Hainan Shuangcheng Pharmaceutical issued an announcement saying that it agreed to its holding subsidiary Ningbo Shuangcheng Pharmaceutical, which plans to acquire Memantine Hydrochloride Tablets (5 mg) for RMB 6 million.
, 10mg) related specific intellectual property rights and production technologies in the designated area were granted to Baishan Pharmaceutical (Huzhou)
.
On the 25th, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to 32.
0988 million yuan.
The price will transfer 4.
9383% of the equity held in Minowei to Pingtan Wenzhou Ruiji Investment Partnership (Limited Partnership) and Pingtan Fanrun Enterprise Management Partnership (Limited Partnership).
In general, a large number of domestic and foreign pharmaceutical companies have In the sale or transfer of related businesses, some of them have to sell and transfer "returning blood" due to the impact of their performance
.
Others continue to gather resources and relocate
.
It is foreseeable that in 2022, the competition in the pharmaceutical market will be Disclaimer
: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
